Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…
Ovarian Cancer – Current Treatment – Current Treatment: Physician Insights – Ovarian Cancer (US)
Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…
Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…